Company News

Nine New Abstracts Featuring MyoStrain Presented at SCMR 2019

February 10, 2019
Company News

BELLEVUE, W.A., February 10, 2019 – Nine different abstracts utilizing Myocardial Solutions’ MyoStrain® were presented at Society for Cardiovascular Magnetic Resonance (SCMR) 2019 22nd Annual Scientific Sessions in Bellevue, Washington on February 6th-9th, 2019. The papers span a variety of subjects including MyoStrain reproducibility, comparison to existing methods, ease of training as well as managing cardiac treatment of chemotherapy and obese patients. Two papers were selected to be presented on the podium: Dr. Olga Toro-Salazar’s (Connecticut Children’s Medical Center) abstract that focused on identification of heart failure risk in childhood cancer survivors exposed to anthracycline therapy and Corinna Else’s (Berlin Heart) abstract analyzing MyoStrain’s inter-scan and intra-scan reproducibility.

More detail of the abstracts are listed below:

Title: Predicting the severity of subclinical chemotherapy-induced cardiotoxicity using Fast-SENC segmental myocardial strain

Citation: Geršak B, et al.  Predicting the severity of subclinical chemotherapy-induced cardiotoxicity using Fast-SENC segmental myocardial strain — An interim report (NCT03543228). SCMR 2019. (n=40)

Title: Strain Segmental Dysfunction for Identification of Heart Failure risk in Childhood Cancer Survivors Exposed to Anthracycline Therapy

Citation: Toro-Salazar O, et al.  Strain Segmental Dysfunction for Identification of Heart Failure risk in Childhood Cancer Survivors Exposed to Anthracycline Therapy.  SCMR 2019 (n=87)

Title: Detection of regional wall motion changes that precedes wall thickening using Strain-Encoded (SENC) CMR with intermediate-dose Dobutamine stress

Citation: Kawaji K, et al.  Detection of regional wall motion changes that precedes wall thickening using Strain-Encoded (SENC) CMR with intermediate-dose Dobutamine stress.  SCMR 2019. (n=29)

Title: Fast strain-encoded cardiac magnetic resonance imaging: a multi-vendor, multi-center study on reproducibility and comparability

Citation: Erley J, et al. Fast strain-encoded cardiac magnetic resonance imaging: a multi-vendor, multi-center study on reproducibility and comparability.  SCMR 2019 (n=15)

Title: Impact of Obesity on Segmental Left Ventricular Strain Using Cardiac MRI Fast-SENC

Citation: Hoff EJ, et al.  Impact of Obesity on Segmental Left Ventricular Strain Using Cardiac MRI Fast-SENC. SCMR 2019. (n=76)

Title: Impact of experience and training on variance of LV parameters estimated using fast-SENC cardiac MRI

Citation: Kelle S, et al.  Impact of experience and training on variance of LV parameters estimated using fast-SENC cardiac MRI.  SCMR 2019.

Title: Planning & scanning techniques to ensure standardization and efficiency of fast strain-encoded CMR imaging

Citation: Else C, et al.  Planning & scanning techniques to ensure standardization and efficiency of fast strain-encoded CMR imaging.  SCMR 2019 Technologist Session.

Title: Is abnormal global longitudinal strain associated with the presence of late gadolinium enhancement: a comparison of strain encoded cardiac magnetic resonance and 2-dimensional echocardiography

Citation: Tapaskar N, et al. Is abnormal global longitudinal strain associated with the presence of late gadolinium enhancement: a comparison of strain encoded cardiac magnetic resonance and 2-dimensional echocardiography. SCMR 2019. (n=50)

Title: Left and Right Ventricular Assessment of Longitudinal Myocardial Strain: A Comparison of Strain-Encoded Cardiac Magnetic Resonance and Speckle Tracking Echocardiography

Citation: Erley J, et al.  Left and Right Ventricular Assessment of Longitudinal Myocardial Strain: A Comparison of Strain-Encoded Cardiac Magnetic Resonance and Speckle Tracking Echocardiography. SCMR 2019. (n=46)

Media Contact

Taylor Solomon
PR@myocardialsolutions.com
919.623.0973

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 500 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.